Evidence map›Paper›PMID 41273442›Full record

ReviewRadiation and environmental biophysics2026

Radiation exposure facilities for radiobiology in Europe: availability, capabilities, and limitations.

Tom Unterleiter, Maya Shariff, Michael Rückert, Lena Winterling, Laura Ruspeckhofer, Thomas Weissmann, Florian Putz, Rainer Fietkau, Christoph Bert, Udo S Gaipl and 1 more

Abstract readReview
In one paragraph

Review in Radiation and environmental biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tom UnterleiterDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Maya ShariffDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0002-3963-1059
Michael RückertDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0002-9605-4841
Lena WinterlingDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Laura RuspeckhoferDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Thomas WeissmannDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0002-1443-5422
Florian PutzDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0003-3966-2872
Rainer FietkauDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Christoph BertDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0002-8539-6600
Udo S GaiplDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0001-6375-5476
Lisa DelochDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. Lisa.deloch@uk-erlangen.de.ORCID 0000-0002-5577-2302

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Experimental radiobiology studies rely on exposure platforms that replicate real-world scenarios, yet information on their availability and biological suitability is often fragmented. We thus aimed to map capabilities, access routes, and limitations of European irradiation facilities, with a focus on Germany and briefly contextualized it with selected platforms in the United States of America (U.S.). Single-source systems (X-ray, gamma, alpha/beta) are widely available for cell/animal work, but mixed-beam platforms with controlled conditions and traceable dosimetry are scarce and oversubscribed while alpha/radon analogue setups vary in geometry and atmosphere control, hindering comparability. Large user facilities (reactors, cyclotrons, space-simulation) offer powerful modalities but often lack clearly documented biological access procedures. Here, the selected U.S. facilities provide more explicit user pathways (proposal, fee-for-service, programmatic access). Priorities for Europe should thus include standardized, incubator-compatible mixed-beam systems; a more harmonized reporting of dosimetry/environmental parameters; and a better visibility of biological access in infrastructure catalogues. Ongoing coordination initiatives can underpin these improvements, strengthening reproducibility and access.

Indexed as

Radiation ExposureRadiobiologyEuropeHumansAlpha-RadiationExperimental setupsMixed-BeamRadiation protectionRadiation researchRadon

Identifiers

PMID41273442
PMCPMC13135533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.